CNS Pipeline And Late Stage Approvals Will Drive Long Term Neuroscience Upside

Catalysts

About Axsome Therapeutics

Axsome Therapeutics develops and commercializes innovative neuroscience therapies targeting serious central nervous system disorders.

What are the underlying business or industry changes driving this perspective?

• Rapid prescription and revenue growth for AUVELITY and SUNOSI, outpacing their underlying markets and supported by expanding payer coverage and a national DTC campaign, positions Axsome for sustained top line acceleration and operating leverage that can improve earnings.
• Multiple late stage programs, including AXS-05 for Alzheimer's disease agitation and AXS-12 for narcolepsy, are advancing toward potential approvals that could unlock large, underserved markets and diversify revenue away from a single product dependence.
• Growing recognition and diagnosis of brain health conditions such as depression, sleep disorders and cognitive impairment, combined with persistent unmet medical need, support durable demand for Axsome's differentiated CNS portfolio and can drive long term revenue visibility.
• Strong commercial execution with efficient, overlapping sales infrastructure across psychiatry, neurology and sleep medicine creates high cross brand synergies, which can enhance net margins as incremental launches scale on largely fixed commercial costs.
• A deep pipeline of additional solriamfetol and AXS-14 indications, together with long exclusivity periods for current products, supports a multi year horizon of potential label expansions and lifecycle management that can extend growth duration and support rising cash flows.

Assumptions

This narrative explores a more optimistic perspective on Axsome Therapeutics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Axsome Therapeutics's revenue will grow by 64.6% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -40.9% today to 55.5% in 3 years time.
• The bullish analysts expect earnings to reach $1.4 billion (and earnings per share of $25.0) by about December 2028, up from $-229.5 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $131.8 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 11.0x on those 2028 earnings, up from -33.7x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 19.9x.
• The bullish analysts expect the number of shares outstanding to grow by 3.38% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Axsome is still generating net losses despite rapid revenue growth, and sustained high selling, general and administrative expenses from DTC advertising, sales force expansion and multiple concurrent launches could delay or prevent the transition to cash flow positivity, limiting future earnings.
• The long term growth story relies heavily on successful late stage regulatory outcomes for AXS-05 in Alzheimer's disease agitation, AXS-12 in narcolepsy and multiple solriamfetol and AXS-14 indications, and any clinical failure, regulatory delay, standard review outcome or lack of priority review could materially reduce expected future revenue and earnings.
• Discounting trends and payer dynamics already show AUVELITY and SUNOSI gross to net in the high 40 percent range and expected to rise to the low 50 percent range, while SYMBRAVO’s launch phase gross to net is in the mid 70 percent range. If pricing pressure and access concessions intensify over time, net revenue and margins could be structurally lower than bullish expectations.
• Axsome’s strategy depends on leveraging a single commercial infrastructure across psychiatry, neurology, sleep and long term care settings. If sales force capacity, promotional effectiveness or long term care build out fall short as more products and indications come online, the company may have to increase commercial spending more than anticipated, compressing operating margins and earnings.
• The company is expanding into increasingly competitive and crowded CNS markets such as migraine, narcolepsy, ADHD and Alzheimer’s disease agitation. If rival therapies, including new mechanisms like orexin agonists or entrenched brands, capture a disproportionate share of long term demand, Axsome’s products could underperform expectations, pressuring long run revenue growth and profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Axsome Therapeutics is $223.0, which represents up to two standard deviations above the consensus price target of $181.59. This valuation is based on what can be assumed as the expectations of Axsome Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $223.0, and the most bearish reporting a price target of just $148.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2028, revenues will be $2.5 billion, earnings will come to $1.4 billion, and it would be trading on a PE ratio of 11.0x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $153.64, the analyst price target of $223.0 is 31.1% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.